{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T23:27:58Z","timestamp":1772666878153,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-1090-3","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T09:40:03Z","timestamp":1540201203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?"],"prefix":"10.1186","volume":"19","author":[{"given":"Antonio","family":"Pisani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"1090_CR1","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359:1477\u201385.","journal-title":"N Engl J Med"},{"key":"1090_CR2","first-page":"S93","volume":"63","author":"JJ Grantham","year":"1997","unstructured":"Grantham JJ. Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int Suppl. 1997;63:S93\u20137.","journal-title":"Kidney Int Suppl"},{"key":"1090_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2215\/CJN.00330705","volume":"1","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factordetermining clinical outcomes. Clin J Am Soc Nephrol. 2006;1:148\u201357.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"1090_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):820\u20139.","journal-title":"N Engl J Med"},{"key":"1090_CR5","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebocontrolled, multicentre trial. Lancet. 2013;382:1485\u201395.","journal-title":"Lancet"},{"key":"1090_CR6","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"1090_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/ki.1996.304","volume":"50","author":"CJ Davidow","year":"1996","unstructured":"Davidow CJ, Maser RL, Rome LA, Calvet JP, Grantham JJ. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int. 1996;50:208\u201318.","journal-title":"Kidney Int"},{"key":"1090_CR8","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1523-1755.2004.00967.x","volume":"66","author":"H Li","year":"2004","unstructured":"Li H, Findlay IA, Sheppard DN. The relationship between cell proliferation, cl secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int. 2004;66:1926\u201338.","journal-title":"Kidney Int"},{"key":"1090_CR9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1681\/ASN.2007070828","volume":"19","author":"B Yang","year":"2008","unstructured":"Yang B, Sonawane ND, Zhao D, Somlo S, Verkman AS. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:1300\u201310.","journal-title":"J Am Soc Nephrol"},{"key":"1090_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1172\/JCI9622","volume":"105","author":"KR Hallows","year":"2000","unstructured":"Hallows KR, Raghuram V, Kemp BE, Witters LA, Foskett JK. Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP activated protein kinase. J Clin Invest. 2000;105:1711\u201321.","journal-title":"J Clin Invest"},{"key":"1090_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G Zhou","year":"2001","unstructured":"Zhou G, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167\u201374.","journal-title":"J Clin Invest"},{"key":"1090_CR12","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1073\/pnas.0509694103","volume":"103","author":"JM Shillingford","year":"2006","unstructured":"Shillingford JM, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA. 2006;103:5466\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"1090_CR13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfu087","volume":"29","author":"C Shaw","year":"2014","unstructured":"Shaw C, Simms RJ, Pitcher D, et al. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrol Dial Transplant. 2014 Oct;29(10):1910\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1090_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"Ron T. Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31(3):337\u201348. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfv456\n                    \n                  .","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"1090_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ki.2015.71","volume":"88","author":"H Bhutani","year":"2015","unstructured":"Bhutani H, Smith V, Rahbari-Oskoui F, et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015;88(1):146\u201351.","journal-title":"Kidney Int"},{"key":"1090_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659\u201361.","journal-title":"FASEB J"},{"key":"1090_CR17","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/0140-6736(92)92503-8","volume":"340","author":"D Ravine","year":"1992","unstructured":"Ravine D, Walker RG, Gibson RN, Forrest SM, Richards RI, Friend K, Sheffield LJ, Kincaid-Smith P, Danks DM. Phenotype and genotype heterogeneity in autosomal dominant polycystic kidney disease. Lancet. 1992;340:1330\u20133.","journal-title":"Lancet"},{"key":"1090_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/01.mnh.0000242172.06459.7c","volume":"15","author":"M Praga","year":"2006","unstructured":"Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006;15:481\u20136.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"1090_CR19","doi-asserted-by":"publisher","first-page":"32533","DOI":"10.1371\/journal.pone.0032533","volume":"7","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Gaspari F, Cannata A, et al. Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. PLoS One. 2012;7(2):32533.","journal-title":"PLoS One"},{"key":"1090_CR20","doi-asserted-by":"crossref","unstructured":"Salpeter S, Greyber E, Pasternak G et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;(1):CD002967.","DOI":"10.1002\/14651858.CD002967.pub2"},{"issue":"10","key":"1090_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","volume":"75","author":"Ulrike Hostalek","year":"2015","unstructured":"Hostalek U, Gwilt M, Hidelmann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2005;75(10):1071\u201394.","journal-title":"Drugs"},{"key":"1090_CR22","doi-asserted-by":"crossref","unstructured":"Mauras N, DelGiorno C, Hossain J, Bird K, Killen K, Marinbraum D, Weltman A, Damaso L, Balagopa P. Metformin use in children with obesity and normal glucose tolerance -- effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab. 2012;25(1-2):33\u201340.","DOI":"10.1515\/jpem-2011-0450"},{"issue":"9","key":"1090_CR23","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/jcph.699","volume":"56","author":"Kyungho Jang","year":"2016","unstructured":"Jang K, Chung H, Yoon J, Moon S, Yoon SH Yu KS, Kim K, Chung JY. Pharmacokinetics, safety, and tolerability of metformin in healthy elderly subjects. J Clin Pharmacol. 2016;56(9):1104\u201310.","journal-title":"The Journal of Clinical Pharmacology"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1090-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:14:43Z","timestamp":1571703283000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1090-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1090-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"27 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by local ethic committee (Carlo Romano, University Federico II of Naples, number 17\/15); informed and written consent for treatment of data was obtained by all the patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"282"}}